Better diabetic retinopathy outcomes seen with monthly ranibizumab

09/6/2013 | Medscape (free registration)

Data on diabetic retinopathy patients showed those who received monthly ranibizumab treatment were more likely than those who received sham injections to attain improvements in vision and disease severity at three years. Researchers also found patients in the ranibizumab arm were three times less likely to develop proliferative diabetic retinopathy than those in the control group. The findings were presented at the American Society of Retina Specialists meeting.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT